Oruka Therapeutics' Shares Hit 52-Week High, 4Q Loss Narrower Than Expected

Dow Jones

Yesterday

By Kelly Cloonan

Shares of Oruka Therapeutics gained after the company logged a narrower fourth-quarter loss than Wall Street expected as it made progress with trials for its leading programs.

The stock climbed 22% to $39 on Friday after touching a 52-week high of $39.66 earlier in the trading session. Shares have more than tripled in the past year.

The clinical-stage biotechnology company posted a net loss of $29.6 million, or 45 cents a share, compared with a loss of $25.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 64 cents a share.

The company, which is developing treatments for chronic skin diseases, said it completed enrollment for a study of one of its leading programs and now expects to report data in the second quarter. Oruka also said it is starting a Phase 2 study for a potential plaque psoriasis treatment and expects to report data from the trial next year.

"We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company," Chief Executive Lawrence Klein said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 13, 2026 11:33 ET (15:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619116717"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619116717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619116717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619116717","market":"fut","top_or_hot":-1,"title":"Oruka Therapeutics' Shares Hit 52-Week High, 4Q Loss Narrower Than Expected","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ORKA\">Oruka Therapeutics</a> gained after the company logged a narrower fourth-quarter loss than Wall Street expected as it made progress with trials for its leading programs. \n</p>\n<p>\n  The stock climbed 22% to $39 on Friday after touching a 52-week high of $39.66 earlier in the trading session. Shares have more than tripled in the past year. \n</p>\n<p>\n  The clinical-stage biotechnology company posted a net loss of $29.6 million, or 45 cents a share, compared with a loss of $25.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 64 cents a share. \n</p>\n<p>\n  The company, which is developing treatments for chronic skin diseases, said it completed enrollment for a study of one of its leading programs and now expects to report data in the second quarter. Oruka also said it is starting a Phase 2 study for a potential plaque psoriasis treatment and expects to report data from the trial next year. \n</p>\n<p>\n  \"We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,\" Chief Executive Lawrence Klein said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2026 11:33 ET (15:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oruka Therapeutics' Shares Hit 52-Week High, 4Q Loss Narrower Than Expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOruka Therapeutics' Shares Hit 52-Week High, 4Q Loss Narrower Than Expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-13 23:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ORKA\">Oruka Therapeutics</a> gained after the company logged a narrower fourth-quarter loss than Wall Street expected as it made progress with trials for its leading programs. \n</p>\n<p>\n  The stock climbed 22% to $39 on Friday after touching a 52-week high of $39.66 earlier in the trading session. Shares have more than tripled in the past year. \n</p>\n<p>\n  The clinical-stage biotechnology company posted a net loss of $29.6 million, or 45 cents a share, compared with a loss of $25.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 64 cents a share. \n</p>\n<p>\n  The company, which is developing treatments for chronic skin diseases, said it completed enrollment for a study of one of its leading programs and now expects to report data in the second quarter. Oruka also said it is starting a Phase 2 study for a potential plaque psoriasis treatment and expects to report data from the trial next year. \n</p>\n<p>\n  \"We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,\" Chief Executive Lawrence Klein said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2026 11:33 ET (15:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619116717","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619116717","pubTimestamp":1773415980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Oruka Therapeutics gained after the company logged a narrower fourth-quarter loss than Wall Street expected as it made progress with trials for its leading programs.The stock climbed 22% to $39 on Friday after touching a 52-week high of $39.66 earlier in the trading session. Shares have more than tripled in the past year.The clinical-stage biotechnology company posted a net loss of $29.6 million, or 45 cents a share, compared with a loss of $25.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 64 cents a share.The company, which is developing treatments for chronic skin diseases, said it completed enrollment for a study of one of its leading programs and now expects to report data in the second quarter. Oruka also said it is starting a Phase 2 study for a potential plaque psoriasis treatment and expects to report data from the trial next year.\"We are very pleased with the progress of both our co-lead programs as we advance into what","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","ORKA":"ORUKA THERAPEUTICS INC"},"translate_title":"Oruka Therapeutics股价创52周新高，第四季度亏损收窄于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORKA":0.9,"LENZ":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Oruka Therapeutics gained after the company logged a narrower fourth-quarter loss than Wall Street expected as it made progress with trials for its leading programs. \n\n\n  The stock climbed 22% to $39 on Friday after touching a 52-week high of $39.66 earlier in the trading session. Shares have more than tripled in the past year. \n\n\n  The clinical-stage biotechnology company posted a net loss of $29.6 million, or 45 cents a share, compared with a loss of $25.8 million, or 49 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 64 cents a share. \n\n\n  The company, which is developing treatments for chronic skin diseases, said it completed enrollment for a study of one of its leading programs and now expects to report data in the second quarter. Oruka also said it is starting a Phase 2 study for a potential plaque psoriasis treatment and expects to report data from the trial next year. \n\n\n  \"We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,\" Chief Executive Lawrence Klein said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 11:33 ET (15:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}